Program
tambotatug pelitecan
Also written as “YL201”, “YL201 for Injection” and “Tambotatug pelitecan”.
Its studies are mostly in Small Cell Lung Carcinoma · Nasopharyngeal Carcinoma · Pancreatic Neoplasms · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Drug pageTambotatug pelitecan: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediLink Therapeutics (Suzhou)its history only | 1212 open or running | phase 3since Sep 23, 2024 | Jun 16, 2022 | Jan 2027phase 2 · NCT07208773 |
| Amgen | 11 open or running | phase 1since Mar 21, 2025 | Mar 21, 2025 | Jun 23, 2031phase 1 · NCT06898957 |
- Named in hoffmann la roche’s own pipeline as
RG6919 tambotatug pelitecan (MediLink)
, phase 1, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Hoffmann-La Roche, Fosun Pharma and Akesobio.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 21, 2025First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT06898957 · 29 enrolled · United States, Canada, China and more
- Jul 10, 2025Named tambotatug pelitecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, YL201
Ahead
- Jun 23, 2031Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06898957
TargetBeta
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically conjugated to an as of yet undisclosed topoisomerase-1 inhibitor via a tumor protease-cleavable linker, with potential antineoplastic ac…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risvutatug rezetecan | Hansoh Pharmaceutical Group | phase 3 | 30 |
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 5 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
The one study Amgen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06898957Small Cell Lung Carcinoma · United States, Canada, China and more | 1 | Active, not recruiting | Jun 23, 2031 | 29 |
How it is read
Names in the registry
- “YL201”, 11 entries
- “YL201 for Injection”, 2 entries
- “Tambotatug pelitecan”, 1 entry
- “YL201 and atezolizumab”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 3 studies
- Nasopharyngeal Carcinoma, 2 studies
- Pancreatic Neoplasms, 1 study
- Esophageal Squamous Cell Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.